RxDoctor Payments Data

Mohammed Ahmed, MD

Rheumatology · Toledo, OHNPI 1093763930

Payments from drug & device makers

$7,394in general payments, 2019–2025

Across 435 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$1K
  • Johnson & Johnson$983
  • Pfizer$737
  • AstraZeneca$485
  • Novartis$391
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$7,25298%
  • Education$1422%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,394 in reported general payments places this provider in the 65th percentile of 255 rheumatology providers in Ohio.

See all rheumatology providers in Ohio

Medicare billing

Part B allowed, 2024
$125,751
Medicare patients
261
Services billed
7,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept136$1,049,182
Humira(Cf) PenAdalimumab67$475,183
HumiraAdalimumab38$261,806
EnbrelEtanercept25$189,219
Orencia ClickjectAbatacept18$158,842
OtezlaApremilast32$151,422
XeljanzTofacitinib Citrate27$149,296
Humira PenAdalimumab13$91,960
Xeljanz XrTofacitinib Citrate14$82,624
MethotrexateMethotrexate Sodium744$20,186
Leflunomide147$9,877
Hydroxychloroquine Sulfate281$9,503
Duloxetine Hcl326$4,755
Colchicine84$4,021
Celecoxib112$2,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$1,451$340,64157 claims
AbbVieHumira$1,122$261,80638 claims
PfizerXeljanz$737$149,29627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 rheumatology providers in Ohio.

Other rheumatology in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →